Public court records · Regulatory sources · Independently maintained Data as of: 2026-10-21 · Not legal advice

In re Pradaxa (Dabigatran Etexilate) Products Liability Litigation Lawsuit

US Archived Last verified 2026-10-21

MDL 2385 · United States District Court for the…

In re Pradaxa (Dabigatran Etexilate) Products Liability Litigation.

This case record is archived. The litigation has concluded (settlement finalized / claims resolved). We keep the page public as a reference — no new case reviews are accepted for this matter.

Overview

In re Pradaxa (Dabigatran Etexilate) Products Liability Litigation

Pradaxa (dabigatran etexilate) is an oral anticoagulant made by Boehringer Ingelheim and the first of the direct thrombin inhibitors. It is used to prevent stroke in patients with nonvalvular atrial fibrillation, to treat and prevent deep vein thrombosis and pulmonary embolism, and to prevent clots after major hip or knee surgery. A defining commercial feature was that, unlike warfarin, it did not require routine monitoring by blood tests. The European Medicines Agency first authorized the drug in 2008, and the U.S. Food and Drug Administration approved it in October 2010 for stroke prevention in nonvalvular atrial fibrillation, after an advisory committee had recommended approval. At the time, no specific antidote existed to reverse dabigatran's anticoagulant effect — a gap later filled by idarucizumab, which received FDA approval in 2015.

The alleged harm

Bleeding is the principal adverse effect of dabigatran, and in the pivotal trial data gastrointestinal bleeding occurred at a meaningfully higher rate than with warfarin. The products liability claims alleged that Pradaxa caused severe — and, as the case caption reflects, "unusual" — bleeding events in patients, particularly elderly patients. The dispute took on a regulatory dimension in 2014, when a series of press investigations accused the privately held Boehringer Ingelheim group of withholding critical information about the need for monitoring to protect patients from severe bleeding. Review of internal company communications by the FDA and the European Medicines Agency reportedly revealed that Boehringer's own researchers had found evidence that serum levels of dabigatran vary widely between patients — data that conflicted with the drug's extensive marketing as a monitor-free anticoagulant.

The litigation: MDL No. 2385, Southern District of Illinois

The Pradaxa claims filed in U.S. federal courts were centralized in 2012. The JPML centralization order is dated August 8, 2012 (reported at 883 F. Supp. 2d 1355), and the consolidated actions were docketed as MDL No. 2385 in the United States District Court for the Southern District of Illinois, under master docket 3:12-md-02385-DRH-SCW, and assigned to Chief Judge David R. Herndon. In the consolidated docket, the common questions — the drug's bleeding profile, the adequacy of warnings to patients and prescribers, and the no-monitoring marketing claim — were addressed through coordinated pretrial proceedings while individual injury claims were held for case-by-case resolution.

While the MDL proceeded, the scientific record continued to develop. In May 2014 the FDA reported the results of a large comparative study of more than 130,000 Medicare patients, concluding that dabigatran was associated with a lower risk of overall mortality, ischemic stroke, and intracranial bleeding than warfarin, with more gastrointestinal bleeding and a similar heart-attack risk, and reiterating that the drug's overall risk–benefit ratio remained favorable. In July 2014 the press investigations into the monitoring data added further pressure on the pending claims.

Outcome

In May 2014, Boehringer Ingelheim and the plaintiffs announced a settlement covering roughly 3,900 claimants. The MDL was wound down thereafter; the docket is recorded as terminated, with the litigation resolved in 2014.

Companies involved

Settlement amounts

No settlement amount is public.

As of 2026-10-21, we have not found a published, reliable settlement amount for this matter. We update this section when amounts appear in court records or verified sources — the change will be logged in the updates section.

Full breakdown: settlement amounts page →

Key dates

  1. January 1, 2014Resolved (year only)

Notable filings

No notable filings recorded yet. Docket entries are added from public court records as they appear.

FAQ

Frequently asked questions about this case record, answered from the public record.

What were the Pradaxa lawsuits about?

Pradaxa (dabigatran) is a blood thinner made by Boehringer Ingelheim. Claimants alleged the drug caused severe bleeding, in part because it was marketed as needing no monitoring while its labeling was reviewed. Federal cases were centralized in MDL 2385 (per the JPML).

How much was the Pradaxa settlement?

In May 2014, Boehringer Ingelheim agreed to settle the bulk of the claims — roughly 3,900 claimants — for $650 million (per Wikipedia and contemporaneous reporting).

Was the Pradaxa case in Illinois?

Yes. MDL 2385 was centralized in the U.S. District Court for the Southern District of Illinois, before Chief Judge David R. Herndon (per the JPML and court record) — which is why Illinois-based Pradaxa law firms are frequently searched.

Can I still file a Pradaxa lawsuit?

The 2014 settlement covered the great majority of claims, and the docket is terminated. Whether an individual claim remains possible depends on statute-of-limitations rules. This is not legal advice — consult an attorney.

Case record — archived

This page is neutral reference material — not legal advice. The litigation for this matter has concluded, so case reviews are closed. For advice on your own situation, contact a licensed attorney in your country.